Movement Alert｜Vertex Pharmaceuticals Rises 3.07% in Regular Trading, FDA Accepts Povetacicept Biologics License Application for IgA Nephropathy

Market Focus06-04 22:13

On June 4, Vertex Pharmaceuticals rose 3.07% in regular trading, trading at $443.81/share, with trading volume of approximately $94.98 million. The rebound follows initial selling pressure earlier in the week after the company announced a key regulatory milestone.

On the news front, the U.S. Food and Drug Administration has formally accepted Vertex Pharmaceuticals' Biologics License Application (BLA) for its candidate drug Povetacicept in the treatment of immunoglobulin A nephropathy (IgA nephropathy), seeking an accelerated approval pathway. The accelerated approval pathway is a mechanism established by the FDA for serious diseases with unmet medical needs, designed to expedite the availability of important therapies. If ultimately approved, Povetacicept could provide a new treatment option for IgA nephropathy patients.

Vertex Pharmaceuticals is a global biotechnology company that has developed approved therapies for cystic fibrosis and sickle cell disease, and continues to advance clinical programs in areas including IgA nephropathy and Type 1 diabetes.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1162419911?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 22:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162419911","market":"us","top_or_hot":-1,"title":"Movement Alert｜Vertex Pharmaceuticals Rises 3.07% in Regular Trading, FDA Accepts Povetacicept Biologics License Application for IgA Nephropathy","media":"Market Focus","content":"<p><p>On June 4, Vertex Pharmaceuticals rose 3.07% in regular trading, trading at $443.81/share, with trading volume of approximately $94.98 million. The rebound follows initial selling pressure earlier in the week after the company announced a key regulatory milestone.</p><p>On the news front, the U.S. Food and Drug Administration has formally accepted Vertex Pharmaceuticals' Biologics License Application (BLA) for its candidate drug Povetacicept in the treatment of immunoglobulin A nephropathy (IgA nephropathy), seeking an accelerated approval pathway. The accelerated approval pathway is a mechanism established by the FDA for serious diseases with unmet medical needs, designed to expedite the availability of important therapies. If ultimately approved, Povetacicept could provide a new treatment option for IgA nephropathy patients.</p><p>Vertex Pharmaceuticals is a global biotechnology company that has developed approved therapies for cystic fibrosis and sickle cell disease, and continues to advance clinical programs in areas including IgA nephropathy and Type 1 diabetes.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Vertex Pharmaceuticals Rises 3.07% in Regular Trading, FDA Accepts Povetacicept Biologics License Application for IgA Nephropathy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Vertex Pharmaceuticals Rises 3.07% in Regular Trading, FDA Accepts Povetacicept Biologics License Application for IgA Nephropathy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-04 22:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 4, Vertex Pharmaceuticals rose 3.07% in regular trading, trading at $443.81/share, with trading volume of approximately $94.98 million. The rebound follows initial selling pressure earlier in the week after the company announced a key regulatory milestone.</p><p>On the news front, the U.S. Food and Drug Administration has formally accepted Vertex Pharmaceuticals' Biologics License Application (BLA) for its candidate drug Povetacicept in the treatment of immunoglobulin A nephropathy (IgA nephropathy), seeking an accelerated approval pathway. The accelerated approval pathway is a mechanism established by the FDA for serious diseases with unmet medical needs, designed to expedite the availability of important therapies. If ultimately approved, Povetacicept could provide a new treatment option for IgA nephropathy patients.</p><p>Vertex Pharmaceuticals is a global biotechnology company that has developed approved therapies for cystic fibrosis and sickle cell disease, and continues to advance clinical programs in areas including IgA nephropathy and Type 1 diabetes.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRTX","symbol_name":"福泰制药","start_time":0,"source_url":"","article_id":"1162419911","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162419911","pubTimestamp":1780582419,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 4, Vertex Pharmaceuticals rose 3.07% in regular trading, trading at $443.81/share, with trading volume of approximately $94.98 million. The rebound follows initial selling pressure earlier in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRTX":"福泰制药"},"translate_title":"动静快讯|Vertex Pharmaceuticals常规交易涨3.07%FDA受理Povetacicept生物制剂用于IgA肾病许可申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRTX":1},"content_text":"On June 4, Vertex Pharmaceuticals rose 3.07% in regular trading, trading at $443.81/share, with trading volume of approximately $94.98 million. The rebound follows initial selling pressure earlier in the week after the company announced a key regulatory milestone.On the news front, the U.S. Food and Drug Administration has formally accepted Vertex Pharmaceuticals' Biologics License Application (BLA) for its candidate drug Povetacicept in the treatment of immunoglobulin A nephropathy (IgA nephropathy), seeking an accelerated approval pathway. The accelerated approval pathway is a mechanism established by the FDA for serious diseases with unmet medical needs, designed to expedite the availability of important therapies. If ultimately approved, Povetacicept could provide a new treatment option for IgA nephropathy patients.Vertex Pharmaceuticals is a global biotechnology company that has developed approved therapies for cystic fibrosis and sickle cell disease, and continues to advance clinical programs in areas including IgA nephropathy and Type 1 diabetes.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1162419911","isCrawlerRequest":true}